NCT00324870View on ClinicalTrials.gov

Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2013

Study Completion Date

November 30, 2013

Conditions
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
Interventions
DRUG

vorinostat

Given orally

DRUG

bevacizumab

Given IV

Trial Locations (3)

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

21801

Peninsula Oncology and Hematology PA, Salisbury

53792

University of Wisconsin Hospital and Clinics, Madison

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00324870 - Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter